Press Releases

PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 25, 2024 , the Company’s Board of Directors approved “inducement” grants to 33 new employees under Rule

PASADENA, Calif. --(BUSINESS WIRE)--Jul. 24, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024 , at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024 .

– Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease – CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical studies of

PASADENA, Calif. --(BUSINESS WIRE)--Jun. 24, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association

- Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10 - Plozasiran achieved a statistically significant reduction in incidence of acute pancreatitis versus placebo - Plozasiran is the company’s first

PASADENA, Calif. --(BUSINESS WIRE)--May 31, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16 th   European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of

- Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 - Data presented at European Atherosclerosis Society 92 nd   Congress and simultaneously published in the New England Journal of Medicine PASADENA, Calif.

- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol - Data presented at European Atherosclerosis Society 92 nd   Congress and simultaneously published in the New England Journal of Medicine PASADENA, Calif.

- ARO-RAGE reduced serum sRAGE by up to 88% in patients with asthma - Additional promising results presented on two preclinical stage programs targeting thymic stromal lymphopoietin (TSLP) and influenza A viruses PASADENA, Calif. --(BUSINESS WIRE)--May 20, 2024-- Arrowhead Pharmaceuticals, Inc.

- Conference Call and Webcast Today, May 9, 2024 , at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 9, 2024-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024 .